Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis-Reference-Cited by-同舟云学术

Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis

Published:2023-02-02 Issue: Volume: Page:
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Rghei Amira D.,Yates Jacob G. E.,Lopes Jordyn A.,Zhan Xuiaoyan,Guilleman Matthew M.,Pei Yanlong,van Lieshout Laura P.,Santry Lisa A.,Bridle Byram W.,Karimi Khalil,Thompson Brad,Susta Leonardo,Crowe James E.,Wootton Sarah K.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.nature.com/articles/s41434-023-00385-2.pdf

Reference61 articles.

1. Cohen C, Zar HJ. Deaths from RSV in young infants-the hidden community burden. Lancet Glob Health. 2022;10:e169–e170.

2. Welliver RC, Checchia PA, Bauman JH, Fernandes AW, Mahadevia PJ, Hall CB. Fatality rates in published reports of RSV hospitalizations among high-risk and otherwise healthy children. Curr Med Res Opin. 2010;26:2175–81.

3. Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017;30:277–319.

4. Zhang S, Akmar LZ, Bailey F, Rath BA, Alchikh M, Schweiger B, et al. Cost of respiratory syncytial virus-associated acute lower respiratory infection management in young children at the regional and global level: a systematic review and meta-analysis. J Infect Dis. 2020;222:S680–S687.

5. Simões EAF, Bont L, Manzoni P, Fauroux B, Paes B, Figueras-Aloy J, et al. Past, present and future approaches to the prevention and treatment of respiratory syncytial virus infection in children. Infect Dis Ther. 2018;7:87–120.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia;Gene Therapy;2024-04-27

2. Development of AAV-delivered broadly neutralizing anti-human ACE2 antibodies against SARS-CoV-2 variants;Molecular Therapy;2023-11